机构：[1]Department of Rheumatology and Immunology, The Fourth Hospital of Hebei Medical University, Hebei Medical University, Shijiazhuang, China临床科室免疫风湿科河北医科大学第四医院[2]Department of Endocrinology, The Fourth Hospital of Hebei Medical University, Hebei Medical University, Shijiazhuang, China临床科室内分泌科河北医科大学第四医院[3]Animal Center, The Fourth Hospital of Hebei Medical University, Hebei Medical University, Shijiazhuang, China河北医科大学第四医院[4]Department of Ultrasound, The Fourth Hospital of Hebei Medical University, Hebei Medical University, Shijiazhuang, China医技科室超声科河北医科大学第四医院
Background: Inflammatory cytokines are related to the occurrence and development of hepatocellular carcinoma (HCC). Objectives: Interleukin 6 (IL-6) is associated with the occurrence and prognosis of HCC, while Dicer inhibits HCC; accordingly, we checked whether Dicer regulates HCC by modulating the IL-6 pathway. Methods: The HCC cells of SMMC-7721 transfected with Dicer overexpression (pCMV-Dicer) and control (pCMV-NC) lentivirus were divided into 3 groups: The SMMC-7721, pCMV-NC, and pCMV-Dicer groups. The assays of cell proliferation, migration, and invasion were performed using cell counting, wound scratch, and transwell chamber assay. The IL-6 level was measured by flow cytometry bead-based immunoassays. All statistical analyses were analyzed using SPSS version 21 by the student t test and 1-way analysis of Results: Dicer inhibited the secretion of IL-6 from HCC cells, as well as the growth of HCC related to proliferation, migration, and invasion. IL-6 incubation with pCMV-NC cells increased proliferation (from 24 hours to 72 hours; P < 0.05), migration (P = 0.008), and invasion (P = 0.85). In addition, IL-6 could reverse the inhibitory effect of Dicer on HCC cells related to proliferation (P < 0.01) and migration (P = 0.006) when incubated with pCMV-Dicer cells, whereas an IL-6 blocker of tocilizumab could enhance the Dicerinduced inhibition related to proliferation (P < 0.05), migration (P = 0.007), and invasion (P = 0.001) when incubated with pCMVDicer cells. Furthermore, Dicer could increase the inhibition efficiency of apatinib on HCC treatment by their cooperation in IL-6 Conclusions: Dicer could inhibit HCC by the IL-6 pathway, which would be a potential target for HCC treatment. The Dicer inducer might be an enhancer of apatinib for HCC treatment.
基金：
Foundation of Hebei Provincial Department of Science and Technology & Hebei Medical University, Shijiazhuang, Hebei
(2020TXZH03), the key research and development projects
of Hebei province (no. 203777109D), and the key medical scientific research projects of Hebei province (no.
20230908).
第一作者机构：[1]Department of Rheumatology and Immunology, The Fourth Hospital of Hebei Medical University, Hebei Medical University, Shijiazhuang, China[2]Department of Endocrinology, The Fourth Hospital of Hebei Medical University, Hebei Medical University, Shijiazhuang, China
通讯作者：
通讯机构：[1]Department of Rheumatology and Immunology, The Fourth Hospital of Hebei Medical University, Hebei Medical University, Shijiazhuang, China[*1]Department of Rheumatology and Immunology, The Fourth Hospital of Hebei Medical University, Hebei Medical University, 12 Jiankang Road, Shijiazhuang 050011, China
推荐引用方式(GB/T 7714)：
Ma Hongfang,Xing Na,Hou Lin,et al.Dicer Inhibits Hepatocellular Carcinoma by Inhibiting the Interleukin 6 Pathway[J].HEPATITIS MONTHLY.2023,23(1):doi:10.5812/hepatmon-134381.
APA：
Ma, Hongfang,Xing, Na,Hou, Lin,Wu, Jianhua,Sha, Ziyue...&Guo, Zhanjun.(2023).Dicer Inhibits Hepatocellular Carcinoma by Inhibiting the Interleukin 6 Pathway.HEPATITIS MONTHLY,23,(1)
MLA：
Ma, Hongfang,et al."Dicer Inhibits Hepatocellular Carcinoma by Inhibiting the Interleukin 6 Pathway".HEPATITIS MONTHLY 23..1(2023)
